Activity
Loop Diagnostics is a biotechnology company dedicated to developing diagnostic tools for the early detection of sepsis, using in vitro cellular immunoassays to identify the disease in its earliest stages.
History
The company was founded by Enrique Hernández, who during his postdoctoral studies at Bellvitge Hospital in Barcelona identified the importance of analyzing the immune system for the early detection of sepsis. After focusing on research on endotoxin tolerance and changes in gene expression associated with sepsis, he developed an innovative technology that enables more accurate and earlier diagnosis. Loop Diagnostics was established in 2018 and has progressed from the development of its first MVP, through clinical trials, patent application, development of industrial prototypes, quality certification, and distribution agreements, to preparation for international commercialization.
Product types
Loop Diagnostics develops in vitro diagnostic devices for the early detection of sepsis. Its flagship product is SeptiLoop, a lateral flow immunoassay that measures a patient's immune response and enables the diagnosis of bacteremia in as little as one hour after infection. SeptiLoop stands out for its early detection, greater accuracy compared to current tests, ease of use at the point of care, and rapid results in less than three hours. The products are currently in the certification phase and are available only for research and performance evaluation.
Mission
Loop Diagnostics' fundamental purpose is to develop diagnostic technologies that enable the early identification of bloodstream infections, with the goal of reducing mortality, patient side effects, antibiotic resistance, and the costs associated with sepsis management. The company seeks to integrate its technology into hospitals to improve clinical outcomes and facilitate early intervention.
